Characteristics and Measurements of BD Patients Receiving VPA Sub-grouped by the Cut-off Point of MCN
| . | MCN ≥ 2.05(n = 17) . | MCN < 2.05(n = 43) . | . | 95% CI . | Comparison . | . |
|---|---|---|---|---|---|---|
| . | Mean ± SD . | Mean ± SD . | t/χ 2 . | (Lower, Upper) . | P value . | P1 value . |
| mtDNA copy no. | 2.18 ± 0.13 | 1.89 ± 0.08 | 10.226 | (0.23, 0.35) | <.001* | <.001* |
| CRP, ng/mL | 5.02 ± 0.55 | 5.43 ± 0.5 | −3.006 | (−0.69, −0.14) | .004* | .010* |
| MetS diagnosis, n (%) | 1 (5.9) | 15 (34.9) | 5.240 | — | .025* | — |
| MetS components, n | 0.94 ± 1.14 | 1.88 ± 1.50 | −2.333 | (−1.75, −0.13) | .023* | — |
| Alda scale (A-B total) | 4.31 ± 3.09 | 2.74 ± 2.05 | 0.677 | (−1.18, 2.32) | .506 | .392 |
| Responder, n (%) | 10 (58.8) | 9 (20.9) | 6.785 | — | .022* | — |
| Cognitive function WCST | ||||||
| Perseverative errors | 9.77 ± 5.23 | 15.91 ± 12.31 | −2.688 | (−10.71, −1.57) | .009* | .020* |
| Completed categories | 2.77 ± 1.64 | 2.02 ± 1.67 | 1.548 | (−0.22, 1.7) | .127 | .175 |
| . | MCN ≥ 2.05(n = 17) . | MCN < 2.05(n = 43) . | . | 95% CI . | Comparison . | . |
|---|---|---|---|---|---|---|
| . | Mean ± SD . | Mean ± SD . | t/χ 2 . | (Lower, Upper) . | P value . | P1 value . |
| mtDNA copy no. | 2.18 ± 0.13 | 1.89 ± 0.08 | 10.226 | (0.23, 0.35) | <.001* | <.001* |
| CRP, ng/mL | 5.02 ± 0.55 | 5.43 ± 0.5 | −3.006 | (−0.69, −0.14) | .004* | .010* |
| MetS diagnosis, n (%) | 1 (5.9) | 15 (34.9) | 5.240 | — | .025* | — |
| MetS components, n | 0.94 ± 1.14 | 1.88 ± 1.50 | −2.333 | (−1.75, −0.13) | .023* | — |
| Alda scale (A-B total) | 4.31 ± 3.09 | 2.74 ± 2.05 | 0.677 | (−1.18, 2.32) | .506 | .392 |
| Responder, n (%) | 10 (58.8) | 9 (20.9) | 6.785 | — | .022* | — |
| Cognitive function WCST | ||||||
| Perseverative errors | 9.77 ± 5.23 | 15.91 ± 12.31 | −2.688 | (−10.71, −1.57) | .009* | .020* |
| Completed categories | 2.77 ± 1.64 | 2.02 ± 1.67 | 1.548 | (−0.22, 1.7) | .127 | .175 |
Abbreviations: 95% CI, 95% confidence interval; CRP, C-reactive protein; MCN, mitochondrial DNA copy number; MetS, metabolic syndrome; VPA, valproate; WCST, Wisconsin card sorting test.
1The P value was obtained using ANCOVA after adjustment for age, sex and VPA concentration. In ANCOVA analysis, age and VPA concentration were continuous variables, and sex and groups (using the cutoff point of 2.05 for the MCN value: MCN ≥ 2.05 or MCN < 2.05) were categorical variables. Clinical measurements, including mtDNA copy number, CRP, Alda scale, and cognitive function, were dependent variables (outcome variables).
*P < .05.
Characteristics and Measurements of BD Patients Receiving VPA Sub-grouped by the Cut-off Point of MCN
| . | MCN ≥ 2.05(n = 17) . | MCN < 2.05(n = 43) . | . | 95% CI . | Comparison . | . |
|---|---|---|---|---|---|---|
| . | Mean ± SD . | Mean ± SD . | t/χ 2 . | (Lower, Upper) . | P value . | P1 value . |
| mtDNA copy no. | 2.18 ± 0.13 | 1.89 ± 0.08 | 10.226 | (0.23, 0.35) | <.001* | <.001* |
| CRP, ng/mL | 5.02 ± 0.55 | 5.43 ± 0.5 | −3.006 | (−0.69, −0.14) | .004* | .010* |
| MetS diagnosis, n (%) | 1 (5.9) | 15 (34.9) | 5.240 | — | .025* | — |
| MetS components, n | 0.94 ± 1.14 | 1.88 ± 1.50 | −2.333 | (−1.75, −0.13) | .023* | — |
| Alda scale (A-B total) | 4.31 ± 3.09 | 2.74 ± 2.05 | 0.677 | (−1.18, 2.32) | .506 | .392 |
| Responder, n (%) | 10 (58.8) | 9 (20.9) | 6.785 | — | .022* | — |
| Cognitive function WCST | ||||||
| Perseverative errors | 9.77 ± 5.23 | 15.91 ± 12.31 | −2.688 | (−10.71, −1.57) | .009* | .020* |
| Completed categories | 2.77 ± 1.64 | 2.02 ± 1.67 | 1.548 | (−0.22, 1.7) | .127 | .175 |
| . | MCN ≥ 2.05(n = 17) . | MCN < 2.05(n = 43) . | . | 95% CI . | Comparison . | . |
|---|---|---|---|---|---|---|
| . | Mean ± SD . | Mean ± SD . | t/χ 2 . | (Lower, Upper) . | P value . | P1 value . |
| mtDNA copy no. | 2.18 ± 0.13 | 1.89 ± 0.08 | 10.226 | (0.23, 0.35) | <.001* | <.001* |
| CRP, ng/mL | 5.02 ± 0.55 | 5.43 ± 0.5 | −3.006 | (−0.69, −0.14) | .004* | .010* |
| MetS diagnosis, n (%) | 1 (5.9) | 15 (34.9) | 5.240 | — | .025* | — |
| MetS components, n | 0.94 ± 1.14 | 1.88 ± 1.50 | −2.333 | (−1.75, −0.13) | .023* | — |
| Alda scale (A-B total) | 4.31 ± 3.09 | 2.74 ± 2.05 | 0.677 | (−1.18, 2.32) | .506 | .392 |
| Responder, n (%) | 10 (58.8) | 9 (20.9) | 6.785 | — | .022* | — |
| Cognitive function WCST | ||||||
| Perseverative errors | 9.77 ± 5.23 | 15.91 ± 12.31 | −2.688 | (−10.71, −1.57) | .009* | .020* |
| Completed categories | 2.77 ± 1.64 | 2.02 ± 1.67 | 1.548 | (−0.22, 1.7) | .127 | .175 |
Abbreviations: 95% CI, 95% confidence interval; CRP, C-reactive protein; MCN, mitochondrial DNA copy number; MetS, metabolic syndrome; VPA, valproate; WCST, Wisconsin card sorting test.
1The P value was obtained using ANCOVA after adjustment for age, sex and VPA concentration. In ANCOVA analysis, age and VPA concentration were continuous variables, and sex and groups (using the cutoff point of 2.05 for the MCN value: MCN ≥ 2.05 or MCN < 2.05) were categorical variables. Clinical measurements, including mtDNA copy number, CRP, Alda scale, and cognitive function, were dependent variables (outcome variables).
*P < .05.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
